New Colonoscopes Are Launched: Designed to Find More Disease and Improve Treatment Capabilities

New colonoscopes designed to find more disease and improve treatment capabilities have been launched by Olympus.

Colonscopes, PCF-H190T and the PCF-HQ190 have received 510 (k) clearance. Olympus is a market leader in products to enable minimally invasive treatments such as Endoscopic Mucosal Resection and Endoscopic Submucosal Dissection procedures that can benefit from the use of state-of-the-art endoscopes. The benefits of HQ Dual Focus imaging and imaging modalities like Narrow Band Imaging (NBI), now available through a smaller diameter colonoscope, combine with capabilities such as retroflexion, to advance procedures and improve colonoscopy.

“With these GI endoscopes, Olympus continues to raise the bar on increased functionality, bringing the market a slimmer diameter endoscope, all while providing imaging excellence toward future innovations,” said Kevin Mancini, Vice President for Endoscopy at Olympus America Inc. “We know our physician customers are excited about these advancements that will improve their access and visualization of the anatomy as well as a growing range of treatment modalities.”

  • The new PCF-H190TL/I endoscope is a slim, short-bending scope that allows for tighter angulation without compromise to the passage of treatment accessories. Used with the EVIS EXERA III imaging platform, the PCF-H190TL/I is an HD device with a 510(k) claim for Narrow Band Imaging (NBI), which indicates NBI as a “high confidence” assist to an experienced endoscopist employing a validated polyp classification system such as the NBI International Colorectal Endoscopic (NICE) classification, aiding in distinguishing diminutive adenomatous polyps from non-adenomatous polyps during colonoscopy. Other features include:
    • Better retroflexion capability, a technique associated with improved adenoma detection rate (ADR).
    • Appropriate channel layout for passage of therapeutic accessories, such as for hemostasis or polypectomy.
    • Improved insertability to minimize patient discomfort.
  • The new PCF-HQ190L/I is equipped with Dual Focus technology for increased mucosal visualization. Used with the EVIS EXERA III imaging platform, the endoscope’s NBI plus its near focus mode is associated with a greater than 90% agreement with pathological analysis in assigning post-polypectomy surveillance following colonoscopy. Other features include:
    • A 170-degree angle of view and a new level of resolving power to support detailed observation and facilitate lesion detection.
    • Responsive Insertion Technology (RIT) to facilitate complete colonoscopies and reduced cecal intubation times through better maneuverability.
    • Built-in ScopeGuide Function to provide real-time 3D visualization of the scope’s position and configuration during insertion, including identification of scope loops as they form.

“Our practice benefits from different endoscopes for different applications,” said Peter V. Draganov, MD, professor of medicine and the director of advanced therapeutic endoscopy at the University of Florida Health, Gainesville, FL. “We are pleased that Olympus continues to fortify its offerings with design, imaging and therapeutic advancements. These short-bending endoscopes are exciting for their potential to drive ADR rates down across the industry.”

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”